Clinical trials: Breast Cancer, suspended
Breast Adenocarcinoma, HER2/Neu Negative
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
This randomized phase III trial studies how well eribulin mesylate or paclitaxel work as first- or second-line therapy in treating patients with stage IIIC-IV breast cancer that has come back.
- Conditions
- Breast Adenocarcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7
- Trial name
- NCT02037529
- Testing
- Eribulin Mesylate, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 39 sites in United States
- Volunteers
- 201 people
- Sponsor
- Academic and Community Cancer Research United